• Hydroxychloroquine Sulfate: Protocol Guide

  2026-08-07

  Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous-compatible research reagent for probing autophagy and TLR7/9 signaling in autoimmune disease research. It is best suited to freshly prepared, short-term aqueous workflows and should be avoided when DMSO or ethanol compatibility, or long-term solution storage, is required.

• RWJ 67657 and the Future of Precision p38 MAPK Inhibition

  2026-08-07

  This thought-leadership article explores the mechanistic precision and translational value of RWJ 67657 (JNJ-3026582), an orally active, isoform-selective p38 MAP kinase inhibitor. Integrating recent structural biology insights, it guides researchers on leveraging RWJ 67657’s dual-action mechanism—simultaneous kinase inhibition and accelerated dephosphorylation—for robust cytokine modulation in inflammatory disease models. The piece contextualizes these advances within the evolving competitive landscape, highlights protocol parameters, and outlines next steps for translational science.

• O-GlcNAcylation Drives Wnt-Induced Glycolytic Bone Anabolism

  2026-08-06

  This study uncovers how Wnt3a signaling rapidly and persistently increases O-GlcNAcylation to reprogram glucose metabolism and promote bone formation. By delineating two temporally distinct signaling axes, the findings highlight O-GlcNAcylation as a critical mediator in osteoblastogenesis and point to new metabolic intervention strategies for bone disorders.

• Canagliflozin Reshapes Mitochondria in Diabetic Kidney Disea

  2026-08-06

  This study demonstrates that canagliflozin, a selective SGLT2 inhibitor, induces profound structural and functional improvements in proximal tubular cell mitochondria in hypertensive–diabetic mice. The findings highlight a mitochondrial mechanism for kidney protection beyond blood glucose lowering, with implications for advanced diabetes and renal research.

• Ridaforolimus (Deforolimus): Deep Mechanism and Senescence I

  2026-08-05

  Explore Ridaforolimus (Deforolimus, MK-8669) as a potent mTOR pathway inhibitor with unique anti-senescence and antiproliferative potential. This article provides advanced insights beyond protocol guides, delving into mechanistic, translational, and assay-level considerations for cancer and aging research.

• P2Y2 Receptor-Mediated Microglial Uptake of Aβ1–42: Mechanis

  2026-08-05

  Kim et al. (2012) identified that nucleotides released from microglia treated with Amyloid β-Peptide (1-42) (Aβ42) promote neighboring microglial migration and enhance Aβ42 uptake through P2Y2 receptor activation. These findings delineate a nucleotide-driven axis for amyloid clearance, highlighting P2Y2 as a potential therapeutic target in Alzheimer's disease research.

• Canagliflozin Reshapes Mitochondrial Networks in Diabetic Ki

  2026-08-04

  Trentin-Sonoda et al. reveal that canagliflozin, beyond its role as an SGLT2 inhibitor and glucose-lowering agent, directly remodels the structure and improves the function of proximal tubular cell mitochondria in hypertensive–diabetic mice. These findings refine the mechanistic understanding of kidney protection in diabetes, highlighting mitochondrial modulation as a key therapeutic avenue.

• Resazurin Sodium Salt: Fluorogenic Redox Indicator for Viabi

  2026-08-04

  Resazurin sodium salt empowers sensitive, scalable cell viability and cytotoxicity assays across diverse platforms—from high-throughput screening to advanced disease modeling. By leveraging its robust fluorogenic properties, researchers can achieve reproducible, high-content results while optimizing workflows for challenging cell types.

• Injectable Hydrogel Enables Curative Chemo-Immunomodulation

  2026-08-03

  This study introduces an injectable, dual-responsive hydrogel that delivers mitoxantrone and Resiquimod (R-848) for synergistic chemo-immunomodulation during tumor ablation. The system addresses key clinical limitations by providing thermal protection, controlled drug release, and robust innate immune activation, resulting in improved ablation efficacy and reduced recurrence risk.

• SGK1 Inhibition: Redefining Vascular and Tumor Research Fron

  2026-08-03

  Explore how EMD638683, a highly selective SGK1 inhibitor, is propelling translational breakthroughs in vascular stiffening and oncology. This thought-leadership article bridges mechanistic insights with strategic guidance, highlighting new experimental avenues and clinical implications for researchers seeking to leverage SGK inhibition in the fight against cardiovascular and oncologic diseases.

• Cannabidiol Attenuates Orofacial Inflammatory Pain via Endoc

  2026-08-02

  This study demonstrates that cannabidiol (CBD) effectively reduces both the sensory and affective dimensions of orofacial inflammatory pain by modulating peripheral and central endocannabinoid pathways. The findings highlight CBD's potential as a multifaceted therapeutic candidate for pain management, with mechanistic insights into FAAH and cannabinoid receptor involvement.

• BHPF as a Novel GPER Inhibitor: Mechanistic Insights in Neur

  2026-08-01

  The reference study uncovers fluorene-9-bisphenol (BHPF) as a direct inhibitor of the G protein-coupled estrogen receptor 1 (GPER), elucidating its binding mechanism and functional consequences in human neuroblastoma cells. This work advances understanding of environmental endocrine disruptors and provides mechanistic detail relevant to estrogen signaling research and neurodegenerative risk assessment.

• Tomivosertib Suppresses Ectopic Activity in Human DRG Neuron

  2026-07-31

  This study delivers the first direct evidence that inhibiting MNK signaling with tomivosertib rapidly suppresses spontaneous activity in human dorsal root ganglion (DRG) neurons from radiculopathy patients. These findings establish a new translational avenue for targeting neuropathic pain at the level of human nociceptor excitability and intracellular signaling.

• Nutlin-3a MDM2 Inhibitor: Applied Workflows & Troubleshootin

  2026-07-31

  Nutlin-3a empowers cancer researchers with precise control over p53 pathway activation and apoptosis induction, enabling reproducible cell-based and in vivo assays. This guide translates bench-proven protocols and troubleshooting strategies for maximizing the impact of Nutlin-3a, a trusted APExBIO MDM2 inhibitor, in advanced cancer research.

• Nicotinamide Adenine Dinucleotide (NAD+): Mechanisms & Bench

  2026-07-30

  Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme acting as an oxidizing agent in metabolic and signaling pathways. APExBIO’s high-purity NAD+ (B1793) supports reproducible research on protein deacetylation and DNA repair. Its use is foundational in cell stress, autophagy, and enzymatic activity assays.

16409 records 1/1094 page Next 12345 下5页 Last page